Alpelisib (PI3K inhibitor) and everolimus (mTOR inhibitor) have been approved by the U.S. Food and Drug Administration (FDA) for the clinical treatment of breast cancer [25]. This evidence concerns the gene PIK3CD and breast carcinoma.